RegulatoryAug 3, 2026, 04:17 PM
AEON Biopharma Regains NYSE American Listing Compliance
AI Summary
AEON Biopharma announced it has regained compliance with NYSE American's continued listing standards, resolving previously identified deficiencies. This was achieved following the completion of an underwritten public offering that generated approximately $13.6 million in net proceeds, with potential for an additional $34.0 million from milestone warrants. The company's stockholders' equity now exceeds the $4.0 million minimum requirement, and the ".BC" indicator will be removed from its trading symbol.
Key Highlights
- Regained compliance with NYSE American's continued listing standards.
- Resolved deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide.
- The ".BC" indicator will be removed from the Company’s trading symbol.
- Compliance achieved following completion of an underwritten public offering.
- Received aggregate net proceeds of approximately $13.6 million from the offering.
- Potential to receive up to an additional $34.0 million from milestone warrants.
- Stockholders’ equity now exceeds the $4.0 million minimum requirement.
Price Impact
More from AEON